PMCB PharmaCyte Biotech, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1157075 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,334.7%
TTM EPS YoY-3,566.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.4%
ROA-39.5%
ROIC (approx.)-27.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.8%
Debt / equity0.00x
Current ratio40.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-30 | FY20252025-04-30 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $391,301 | $438,416 |
| SG&A expense | $4.91M | $3.94M |
| Operating income | -$6.85M | -$4.38M |
| Pretax income | -$19.42M | $30.66M |
| Income tax | $0 | $0 |
| Net income | -$19.42M | $30.66M |
| EPS (basic) | -2.77 | 3.19 |
| EPS (diluted) | -2.77 | 3.19 |
| Weighted avg. shares (diluted) | 8.38M | 7.33M |
| Balance sheet | ||
| Cash & equivalents | $18.60M | $15.17M |
| Short-term investments | $254,010 | $366,316 |
| Current assets | $37.42M | $22.38M |
| Intangibles | $0 | $1.55M |
| Total assets | $46.75M | $55.17M |
| Current liabilities | $826,424 | $2.91M |
| Total liabilities | $11.77M | $3.28M |
| Shareholders' equity | $33.29M | $51.89M |
| Shares outstanding | 10.74M | 6.80M |
| Cash flow statement | ||
| Operating cash flow | -$5.15M | -$2.98M |
| Investing cash flow | $2.00M | -$7.00M |
| Financing cash flow | $6.58M | -$25.03M |
| Stock-based compensation | $892,500 | $0 |
| Share buybacks | $401,625 | $2.54M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.